We report a targeted, cost-effective method to quantify rare single-nucleotide polymorphisms from pooled human genomic DNA using second-generation sequencing. We pooled DNA from 1,111 individuals and targeted four genes to identify rare germline variants. Our base-calling algorithm, SNPSeeker, derived from large deviation theory, detected single-nucleotide polymorphisms present at frequencies below the raw error rate of the sequencing platform.
The cumulative impact of rare variants on common disease is currently unknown, but recent studies have implicated rare genetic variants in many complex traits and diseases. Consequently, it has been suggested that the combined effects of rare deleterious mutations could explain a substantial fraction of the genetic susceptibility to many common diseases 1, 2 . Identifying rare variants necessitates genotyping large populations of individuals, either sequentially (for example, the 1,000 Genomes Project 3 ) or, to minimize cost and time, as a pooled sample. However, it has proven difficult to quantify the prevalence of deleterious alleles in pooled samples. Sanger and array-based resequencing are expensive for the amount of sequencing coverage obtained, and are thus incompatible with large pools. Secondgeneration sequencing has lowered sequencing costs by over 100-fold, but high error rates have hindered the analysis of large pooled samples because it is difficult to distinguish rare variants from sequencing errors.
Owing to cost and time savings, pooled-sample sequencing should be useful for studying rare, human-specific genetic variation in large populations; characterizing deleterious alleles at multiple loci that may impact disease susceptibility and treatment; quantifying the abundance of rare somatic mutations; and identifying germline variants associated with disease state.
We combined molecular biology techniques and computational analysis to achieve targeted resequencing and rare-variant detection in 13 kilobases of DNA per individual from 1,111 individuals using the Illumina Genome Analyzer I. We pooled a normalized amount of DNA isolated from dried blood on 1,111 de-identified Guthrie cards collected for newborn screening. The Missouri Department of Health and Senior Services Institutional Review Board and the Washington University Human Research Protection Office reviewed and approved use of de-identified DNA samples (Supplementary Methods online). Using specific primers (Supplementary Table 1 online), we PCR-amplified 14 loci covering 13.2 kilobases of the SFTPB, TP53, APC and ACTB genes. We ligated amplicons into long concatemers, randomly fragmented them and prepared them for Illumina sequencing according to the manufacturer's protocol. This generated 4.4 Â 10 7 sequences, 83.4% (3.7 Â 10 7 reads ¼ 1.3 gigabases) of which aligned to the reference, allowing for up to two mismatches. To quantify sequencing errors, we included a 1,276 bp region of the pUC19 plasmid as an internal control. We used the first 800 bases to train our algorithm and the remaining 476 bases as a test set. We found that the first 12 bases of each Illumina read contained significantly fewer errors than later bases (Wilcoxon signed-rank test P o 2.2 Â 10 -16 ; Fig. 1a ), so we used only these data to identify sequence variation. However, sequencing errors were still present at a higher frequency than that of a single allele in the pool, making an accurate error model essential to distinguishing bona fide variants from sequencing errors.
As existing second-generation base-calling programs cannot detect and quantify rare variants in large pooled samples, we developed SNPSeeker (Supplementary Software online), an algorithm based on large deviation theory. SNPSeeker uses a secondorder dependency error model for single-nucleotide polymorphism (SNP) identification and takes into account the position in the sequencing read (cycle number) and the identity of the two upstream bases. Consequently, we used only mismatches at bases 3-12 of each sequencing read to identify SNPs (this reduced the effective coverage per allele to 13.8-fold in these experiments). Incorporating quality scores did not improve results beyond these parameters (Supplementary Fig. 1 and Supplementary Results online). For each machine run, we trained a new error model using the internal pUC19 control because we found that error rates varied substantially between machine runs (Fig. 1b) .
The SNPSeeker algorithm greatly improved the specificity of SNP calling ( Supplementary Fig. 2 amplicon. This yielded a specificity of 99.8% and demonstrated that our base-calling algorithm is specific and can accurately model sequencing and PCR errors.
We validated called SNPs by comparing them to prior individual Sanger sequencing data at the SFTPB locus in this cohort 4 and by performing additional TaqMan (Applied Biosystems) assays (Supplementary Tables 2 and 3 online). To estimate the sensitivity of our method, we sequenced a 665-bp region of the SFTPB gene with seven known SNPs. Our method identified all seven SNPs at very similar frequencies to those found by Sanger sequencing. Three of these SNPs were present at o1.5% in this population, demonstrating that this method has the sensitivity to detect rare SNPs in this pooled sample (Supplementary Table 3a) . We also identified two SNP positions within SFTPB that were not identified by Sanger sequencing. We performed individual TaqMan assays on each of these positions, and neither mutation was identified.
In addition to the nine called SNPs in SFTPB, 55 additional SNPs were called in ACTB, TP53 and APC (Supplementary Table 4 online). Of these, 37 (67%) had been previously described in dbSNP (build 128). By chance, one would expect less than one SNP, on average, to be shared between these two sets. Using Fisher's Exact test, we found that the observed degree of overlap was significant (P o 1.3 Â 10 À56 ). Therefore, it is highly likely that the 37 SNPs identified by SNPSeeker and found in dbSNP are bona fide variants. Many of these SNPs were rare: 26 of the 37 dbSNPs that we identified had estimated allele frequencies of less than 1.5% in our population (Supplementary Table 4) . We also performed a comparative genomic analysis of the deleterious nature of the nonsynonymous SNPs identified (Supplementary Results and Supplementary Table 5 online).
To estimate the positive predictive value of our method, we chose seven called SNPs in these genes for independent validation by individual TaqMan genotyping. All seven SNPs were rare in our cohort, with estimated minor allele frequencies (MAFs) of 0.5-1.2%. Three of the selected SNPs have been previously reported in dbSNP, though not in our population, and the remaining four have not been previously described. TaqMan genotyping validated all seven called rare variants ( Supplementary Table 3b ). When combined with SFTPB results, we validated 14/16 predicted SNPs, giving a positive predictive value of 87%. To determine whether the pooled sample sequencing method could be used to accurately quantify allele frequencies, we plotted the predicted versus true MAFs for each of the 14 validated SNPs (Fig. 2) . The observed and predicted frequencies were highly correlated (r 2 ¼ 0.96) across a wide range of frequencies: from a single allele (0.05%) up to several hundred alleles (21.2%). When we plotted predicted SNP average heterozygosities against reported average heterozygosity values for all SNPs in common with dbSNP, the correlation remained strong at r 2 ¼ 0.82 ( Supplementary Fig. 3 online) . These findings indicate that pooled sample sequencing can be used to accurately determine the population frequency of common and rare alleles.
A deeper understanding of genetic variation in the human population will allow us to dissect the causative factors that contribute to a wide array of human disease, understand the genetic characteristics that make us uniquely human and quantify the impact of selection across the human genome throughout history. We resequenced 13,237 bases per 1,111 individuals at approximately 2% of the cost of the original analysis by Sanger sequencing 4 . Notably, this cost savings did not come at the price of sensitivity or accuracy.
The positive predictive value of 87% obtained in this study is consistent with previously published values of 85% 5 and 92% 6 in assays identifying SNPs from multiple organisms via secondgeneration sequencing, but we analyzed over an order of magnitude more individuals (1,111 compared to 2 in ref. 5 and 66 in ref. 6 ) than these studies. The ability to pool DNA from more individuals enables the discovery of rare SNPs, which is important, as most deleterious SNPs are unlikely to be present at frequencies greater than 1%. Furthermore, our method more accurately estimates MAFs (r 2 ¼ 0.96 versus 0.67 in ref. 6) , which is important to accurately identify disease-associated alleles when comparing disease and normal cohorts.
At the SFTBP locus, we detected a single mutant allele in a background of 2,221 wild-type alleles; however, there were not enough singleton alleles in our validation set to determine the sensitivity of our method for the detection of these very rare SNPs (MAF ¼ 0.045% in this cohort) in this population. For applications in which it is important to detect singleton SNPs with a high sensitivity, we recommend choosing a pool size such that singleton mutations are present at frequencies similar to those of the rare SNPs validated here (MAF of 0.5-1.2%).
There are various applications for this method. Sequencing large, random populations at various genetically important loci would enable the study of human-specific variation and selection. Quantification of rare somatic mutations in tumors and precancerous lesions would facilitate improved understanding of tumorigenesis. Finally, sequencing case-control or matched sample cohorts will enable identification of rare mutations associated with complex diseases 1, 2 . Candidate genes can be selected based on prior knowledge 1,2 or they can be informed by genome-wide association studies. Combining pooled-sample sequencing with genomic selection strategies 7-9 makes it possible to move beyond the candidate gene approach and perform a more systematic survey of proteincoding DNA. Such knowledge would be a valuable tool for disease screening, assigning risk stratification, providing longitudinal preventative care and tailoring risk-appropriate therapy.
